You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
CALQUENCE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.
This indication is approved via the provisional approval pathway, based on overall response rate. Full registration for this indication depends on verification and description of clinical benefit in confirmatory trials.CALQUENCE is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Mantle cell lymphoma (MCL),CALQUENCE as monotherapy is indicated for the treatment of patients with mantle cell lymphoma
(MCL) who have received at least one prior therapy.,CALQUENCE in combination with bendamustine and rituximab (BR) is indicated for the treatment
of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for
autologous haematopoietic stem cell transplantation.,Chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL),CALQUENCE as monotherapy is indicated for the treatment of patients with chronic lymphocytic
leukaemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy.,CALQUENCE as monotherapy or in combination with obinutuzumab is indicated for the treatment
of patients with previously untreated chronic lymphocytic leukaemia (CLL)/small lymphocytic
lymphoma (SLL). For details of the combination regimens, see Section 5.1 Pharmacodynamic
properties / Clinical trials.,CALQUENCE in combination with venetoclax with or without obinutuzumab is indicated for the
treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL)/small
lymphocytic lymphoma (SLL). For details of the combination regimens, see Section 5.1
Pharmacodynamic properties / Clinical trials.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April, 1 2026. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
